PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) Trial Rationale and Design
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) Trial Rationale and Design
复制标题
DOI：
10.1161/circheartfailure.112.969071
复制
发表时间：
2012-09-01
影响因子：
9.7
通讯作者：
Braunwald, Eugene
中科院分区：
文献类型：
--
作者：
Redfield, Margaret M.;Borlaug, Barry A.;Braunwald, Eugene
2012年9月，654例循环心力衰竭患者严重受损，这种受损的程度与较高的死亡率相关。15此外，HFpEF的特征是在运动7、14、16或β肾上腺素能刺激期间收缩储备能力显着不足。收缩储备受损与总体运动能力降低、HF症状严重程度和偶发肺水肿有关。七、十八
654 Circ Heart Fail September 2012 significantly impaired, and the extent of this impairment is associated with higher mortality. 15 Furthermore, HFpEF is characterized by dramatic deficits in systolic reserve capacity during exercise7, 14, 16 or β-adrenergic stimulation. 17 Impaired systolic reserve is associated with reduction in overall exercise capacity, HF symptom severity, and incident pulmonary edema. 7, 18